BioSpace News Archive

Biotechnology company Inventprise announced that a Phase 1/2 clinical study of its 25-valent pneumococcal conjugate vaccine has begun in Halifax, Canada.

Sio Gene Therapies Inc. provided financial results for its fiscal second quarter ended September 30, 2022.

Sobi North America announced that the U.S. FDA issued an emergency use authorization for KINERET® for the treatment of COVID-19 in adult patients who are hospitalized with positive results of direct SARS-CoV-2 viral testing with pneumonia, requiring supplemental oxygen, and are at risk of progressing to severe respiratory failure, and are likely to have an increased blood level of a certain suPAR that may be a sign of increased risk of worsening of the disease.

Theriva Biologics announced that it plans to host a conference call on Friday, November 11, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a corporate update.

Rapid Micro Biosystems, Inc. announced its financial results for the third quarter ended September 30, 2022.

Bio-Techne Corporation announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Stephens Annual Investment Conference on Thursday, November 17, 2022, at 10:00 a.m. CST.

Intensity Therapeutics, Inc. along with The Ottawa Hospital and Ontario Institute of Cancer Research, will present updated data from the INVINCIBLE study, a randomized, phase 2 presurgical window of opportunity trial for Intensity’s intratumoral INT230-6 comprising SHAO, vinblastine and cisplatin, that is evaluating clinical and biological effects in patients with early-stage operable breast cancer.

908 Devices continues to equip its life science customers with actionable intelligence at the point-of-need, enabling them to drive advancements in biotherapeutic development.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the third quarter ended September 30, 2022.

Stoke Therapeutics, Inc. today announced that management will hold a webinar and conference call for analysts and investors at 8:30 a.m. Eastern Time on Monday, November 14, 2022.